Chin‐Chou Wang

6.0k total citations
126 papers, 2.0k citations indexed

About

Chin‐Chou Wang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Chin‐Chou Wang has authored 126 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Pulmonary and Respiratory Medicine, 50 papers in Oncology and 22 papers in Epidemiology. Recurrent topics in Chin‐Chou Wang's work include Lung Cancer Treatments and Mutations (41 papers), Lung Cancer Research Studies (20 papers) and Colorectal Cancer Treatments and Studies (19 papers). Chin‐Chou Wang is often cited by papers focused on Lung Cancer Treatments and Mutations (41 papers), Lung Cancer Research Studies (20 papers) and Colorectal Cancer Treatments and Studies (19 papers). Chin‐Chou Wang collaborates with scholars based in Taiwan, United States and United Kingdom. Chin‐Chou Wang's co-authors include Meng‐Chih Lin, Shih‐Feng Liu, Wen‐Feng Fang, Mao‐Chang Su, Yung‐Che Chen, Yu‐Hsiu Chung, Kuo‐Tung Huang, Yu‐Mu Chen, Yi-Hsi Wang and Jien-Wei Liu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Chin‐Chou Wang

125 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chin‐Chou Wang Taiwan 25 804 503 314 307 282 126 2.0k
Meng‐Chih Lin Taiwan 28 1.1k 1.3× 297 0.6× 375 1.2× 402 1.3× 277 1.0× 165 2.7k
David A. Greenwald United States 22 566 0.7× 573 1.1× 285 0.9× 295 1.0× 173 0.6× 76 2.6k
Chong Kin Liam Malaysia 27 1.0k 1.3× 347 0.7× 190 0.6× 319 1.0× 324 1.1× 151 2.0k
D. Lowe United Kingdom 29 681 0.8× 577 1.1× 232 0.7× 237 0.8× 100 0.4× 76 3.5k
Paolo Trerotoli Italy 29 368 0.5× 245 0.5× 337 1.1× 376 1.2× 148 0.5× 113 2.4k
Shih‐Feng Liu Taiwan 23 575 0.7× 139 0.3× 223 0.7× 241 0.8× 339 1.2× 101 1.6k
Yu‐Jun Chang Taiwan 28 325 0.4× 178 0.4× 245 0.8× 370 1.2× 176 0.6× 150 2.4k
W. Craig Hooper United States 43 358 0.4× 215 0.4× 555 1.8× 634 2.1× 253 0.9× 130 5.2k
Mitchell S. Cappell United States 39 1.4k 1.7× 908 1.8× 208 0.7× 837 2.7× 310 1.1× 251 5.1k
Chien‐Yu Lin Taiwan 31 468 0.6× 303 0.6× 553 1.8× 334 1.1× 500 1.8× 134 2.9k

Countries citing papers authored by Chin‐Chou Wang

Since Specialization
Citations

This map shows the geographic impact of Chin‐Chou Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chin‐Chou Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chin‐Chou Wang more than expected).

Fields of papers citing papers by Chin‐Chou Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chin‐Chou Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chin‐Chou Wang. The network helps show where Chin‐Chou Wang may publish in the future.

Co-authorship network of co-authors of Chin‐Chou Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Chin‐Chou Wang. A scholar is included among the top collaborators of Chin‐Chou Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chin‐Chou Wang. Chin‐Chou Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
3.
Huang, Wan‐Ting, Chia‐Te Kung, Fu‐Jen Cheng, et al.. (2024). Association between exposure to organophosphate flame retardants and epidermal growth factor receptor expression in lung cancer patients. Thoracic Cancer. 15(24). 1805–1814. 4 indexed citations
4.
5.
Huang, Chi‐Hsien, Chin‐Chou Wang, Fu‐Tsai Chung, et al.. (2023). Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC. Scientific Reports. 13(1). 20323–20323. 8 indexed citations
6.
7.
Kuo, Chih‐Hsi S., Chi‐Hsien Huang, Chin‐Chou Wang, et al.. (2022). Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation. Cancers. 14(2). 316–316. 7 indexed citations
8.
Chiu, Chi‐Tsun, Chih‐Liang Wang, Tsung‐Ying Yang, et al.. (2022). Overall Survival Improvement in Patients with Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer and Bone Metastasis Treated with Denosumab. Cancers. 14(14). 3470–3470. 9 indexed citations
9.
Lin, Yu‐Ching, Li‐Chung Chiu, Shih‐Hong Li, et al.. (2022). Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study. Therapeutic Advances in Medical Oncology. 14. 4287525310–4287525310. 7 indexed citations
10.
Wang, Chin‐Chou, Wan‐Jou Shen, Gangga Anuraga, et al.. (2022). Novel Potential Therapeutic Targets of PTPN Families for Lung Cancer. Journal of Personalized Medicine. 12(12). 1947–1947. 6 indexed citations
11.
Kuo, Chih‐Hsi S., Chin‐Chou Wang, John Wen‐Cheng Chang, et al.. (2021). A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed. BMC Cancer. 21(1). 309–309. 5 indexed citations
13.
Huang, Chi‐Hsien, Chin‐Chou Wang, Chien‐Ying Liu, et al.. (2021). First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 13. 4277447742–4277447742. 17 indexed citations
14.
Wang, Chin‐Chou, Kuo‐Tung Huang, Huang‐Chih Chang, et al.. (2021). Comprehensive analysis of PD‐L1 in non‐small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue. Thoracic Cancer. 13(1). 38–47. 7 indexed citations
15.
Kung, Chia‐Te, Chien‐Te Lee, Huey‐Ling You, et al.. (2021). The Risk Factors of Blood Cadmium Elevation in Chronic Kidney Disease. International Journal of Environmental Research and Public Health. 18(23). 12337–12337. 13 indexed citations
16.
Wang, Chin‐Chou, Chien‐Ying Liu, Chih‐Liang Wang, et al.. (2020). Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer. Thoracic Cancer. 11(6). 1541–1549. 28 indexed citations
17.
Chen, Yu‐Mu, Chiung-Yu Lin, Wen‐Feng Fang, et al.. (2017). The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer. PLoS ONE. 12(6). e0178676–e0178676. 24 indexed citations
18.
Tang, Woung‐Ru, Sien‐Hung Yang, Chih‐Teng Yu, et al.. (2016). Long-Term Effectiveness of Combined Treatment with Traditional Chinese Medicine and Western Medicine on the Prognosis of Patients with Lung Cancer. The Journal of Alternative and Complementary Medicine. 22(3). 212–222. 23 indexed citations
20.
Lee, Fan-Yen, et al.. (2013). An Obesity Paradox of Asian Body Mass Index after Cardiac Surgery: Arterial Oxygenations in Duration of Mechanic Ventilation. The Scientific World JOURNAL. 2013(1). 426097–426097. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026